GSK Consumer Healthcare Trading Profit Boosted 23% By Block Drug
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Block Drug acquisition drove trading profit for the consumer healthcare business up 23% to $798 mil. in 2001